Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004030 · ClinicalTrials.gov registry record · Phase 1
VX-853 in Treating Patients With Solid Tumors Who Are Receiving Liposomal Doxorubicin
A Phase 1 study, sponsored by Georgetown University.
- Completed
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
NCT00004030 is a Phase 1 study that has completed, run by Georgetown University. The registered enrollment target is 45 participants.
The verdict
NCT00004030, a Phase 1 study, has completed, sponsored by Georgetown University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of VX-853 in treating patients who have solid tumors who are receiving liposomal doxorubicin.
Interventions
- DRUG pegylated liposomal doxorubicin hydrochloride
- DRUG VX-853
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 1996-03 |
| Est. Completion | 2001-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004030
The ClinicalTrials.gov registry entry for NCT00004030 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Georgetown University, which has 227 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which pegylated liposomal doxorubicin hydrochloride is the first listed.
NCT00004030 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004030 about?
NCT00004030 is a clinical study titled "VX-853 in Treating Patients With Solid Tumors Who Are Receiving Liposomal Doxorubicin". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of VX-853 in treating patients who have solid tumors who are receiving liposomal doxorubicin.
What is the current status of trial NCT00004030?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 1996-03. Estimated completion is 2001-01.
What interventions are being tested in trial NCT00004030?
The interventions under investigation include: pegylated liposomal doxorubicin hydrochloride (DRUG), VX-853 (DRUG).
Who is sponsoring clinical trial NCT00004030?
This trial is sponsored by Georgetown University, which has 227 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.